Researchers challenge conventional understanding of cause of Parkinson's

NewsGuard 100/100 Score

An international team of researchers involving members of the University of Basel's Biozentrum challenges the conventional understanding of the cause of Parkinson's disease. The researchers have shown that the inclusions in the brain's neurons, characteristic of Parkinson's disease, are comprised of a membranous medley rather than protein fibrils. The recently published study in "Nature Neuroscience" raises new questions about the etiology of Parkinson's disease.

Parkinson's disease is one of the most common neurodegenerative diseases worldwide. This disease is typically accompanied by motor defects such as the tremor of arms and legs, slowness of movements and muscle rigidity, which occur together with other non-motor symptoms. A characteristic of this progressively worsening and currently unstoppable disease are neuronal inclusions, so called Lewy bodies, that occur in many regions of the brain in the course of the disease. For decades, it was assumed that Parkinson's disease is caused by deposits of insoluble fibrils consisting of the protein alpha-synculein in the Lewy bodies.

Membrane fragments instead of protein fibrils
In their current study, the Dutch, German and Swiss researchers, including Prof. Henning Stahlberg's team, refute this long held common thesis. Using state-of-the-art electron microscopes, they have been able to show that the Lewy bodies contain mainly membrane fragments, lipids and other cellular material instead of the anticipated fibrils.

We used correlative light and electron microscopy and other advanced light microscopy methods to take a closer look at the brain of deceased Parkinson's patients and discovered that the Lewy bodies consist mainly of membrane fragments from mitochondria and other organelles, but have in most cases no or only negligible quantities of protein fibrils. The discovery that alpha-synuclein did not present in the form of fibrils was unexpected for us and the entire research field."

Prof. Henning Stahlberg, University of Basel

Currently, the researchers do not know yet where and in what form the protein alpha-synuclein is hidden amongst the membrane fragments and how it is involved in the formation of Lewy bodies. However, their work indicates that the laboratory-based model of alpha-synuclein fibrils as a cause and mechanism of Parkinson's disease should be revisited. "Our finding indicates that in order to uncover the causes of a disease one needs to be more strongly guided by the exploration of the pathology in humans," explains Stahlberg.

Ultrastructural insights into cell organelles
"The questions why it has taken so long to better characterize Lewy bodies, can perhaps be answered with the previous sample preparation and electron microscopy methods. Today's technologies enable us to have a much more detailed look into the morphology of human brain," explains Stahlberg. "The big question for us now is: How does alpha-synuclein contribute to the formation of Lewy bodies, if not present in form of fibrils?"

With their work, the researchers raise many new questions regarding the role of the Lewy bodies in the etiology of Parkinson's disease. The insights into such intracellular structures also provide important clues for potential therapeutic approaches to prevent or stop the formation and propagation of Lewy pathology in the brain.

Source:
Journal reference:

Sarah, H. et al. (2019) Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nature Neuroscience. doi.org/10.1038/s41593-019-0423-2

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New tool hunts for Alzheimer's clues in gut microbiome